Phase 1b study of U3-1287 in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)

Trial Profile

Phase 1b study of U3-1287 in combination with erlotinib in subjects with advanced non-small cell lung cancer (NSCLC)

Completed
Phase of Trial: Phase I

Latest Information Update: 25 May 2016

At a glance

  • Drugs Patritumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 25 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top